Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will speak in the Water Tower Research Fireside Chat on Monday, December 15, 2025 at 1:00 PM ET.

The discussion will cover the final data from Anixa's Phase 1 breast cancer vaccine trial (to be presented December 11, 2025 at the San Antonio Breast Cancer Symposium), the implications of the retired protein strategy for cancer vaccines, and next steps for vaccine development. The event is open to investors and registration is available through Water Tower Research.

Key Figures

Fireside chat date December 15, 2025 Water Tower Research Fireside Chat

Event time 1:00 pm ET Scheduled start time of Fireside Chat

Phase Phase 1 Breast cancer vaccine trial with final data to be discussed

Price change -3.07% Move prior to this announcement

Relative volume 2.03x Today’s volume vs 20-day average before news

52-week high gap -7.27% Price vs 52-week high before news

Net tangible book value $0.46 per share As of July 31, 2025 from S-3 filing

Total estimated offering costs $96,146 Estimated expenses in S-3 shelf registration

Market Reality Check

$5.13 Last Close

Volume Volume 464,390 is 2.03x the 20-day average of 229,003, indicating elevated trading activity ahead of this neutral event update. high

Technical Shares trade above the 200-day MA of 3.32 and are 7.27% below the 52-week high, keeping the stock near the upper end of its yearly range.

Peers on Argus

While ANIX was down 3.07%, several biotech peers were positive, including STTK +6.8%, SRZN +3.76%, PYXS +3.37%, and TCRX +1.5%, with ADAG -4.3%. This points to stock-specific trading rather than a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 17	CAR-T naming milestone	Positive	+2.2%	WHO approval of INN for FSHR-targeted CAR-T ovarian cancer therapy.
Nov 12	Patent extension	Positive	-4.6%	Key U.S. patent extending breast cancer vaccine IP into mid-2040s.
Nov 10	Investor fireside chat	Neutral	+0.0%	Announcement of investor fireside chat covering programs and trial status.
Nov 5	Data transfer deal	Positive	+2.5%	Data transfer agreement and plan to move breast cancer vaccine to Phase 2.
Oct 23	Investor conference	Positive	+3.5%	Planned presentation at Spartan Capital investor conference to reach new investors.

Pattern Detected

Recent news has been largely positive (IP, trial progress, WHO naming), with price reactions mostly modestly positive or flat and one notable negative move on a positive patent update, indicating occasionally inconsistent alignment between upbeat news and near-term price action.

Recent Company History

Over the last few months, Anixa reported several milestones across its programs. On Nov 5, 2025, it executed a data transfer agreement to assume IND sponsorship and advance its breast cancer vaccine to Phase 2, with encouraging Phase 1 immune-response data and final results slated for Dec 11, 2025 (stock +2.52%). A new WHO International Nonproprietary Name for its ovarian cancer CAR-T therapy on Nov 17, 2025 saw a 2.19% gain. A patent win on breast cancer vaccine IP led to a 4.57% decline, showing that positive developments have produced mixed short-term reactions.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-10

Anixa filed an effective Form S-3 shelf on Sep 10, 2025, allowing it to offer securities such as common stock, preferred stock, warrants, subscription rights, depositary shares, purchase contracts, and units over time, providing flexibility for future capital raising that could affect existing shareholders’ ownership stakes.

Market Pulse Summary

The stock is up +5.1% following this news. A strong positive reaction aligns with growing investor focus on Anixa’s breast cancer vaccine program, especially with final Phase 1 data being highlighted at the San Antonio Breast Cancer Symposium and discussed on December 15, 2025. However, prior news occasionally produced mixed price responses, and an effective S-3 shelf filed on September 10, 2025 provides capacity for future securities offerings that could influence longer-term returns.

Key Terms

phase 1 medical

"The final data from Anixa's Phase 1 breast cancer vaccine trial"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

breast cancer vaccine medical

"The final data from Anixa's Phase 1 breast cancer vaccine trial"

A breast cancer vaccine is a drug that teaches the body’s immune system to recognize and attack breast cancer cells, similar to training guard dogs to spot a specific intruder. Investors watch these vaccines because successful clinical results, regulatory approvals, or clear signs of effectiveness can transform treatment options, drive future sales, and sharply affect a developer’s valuation and stock price.

cancer vaccines medical

"Implications for the application of the retired protein strategy for cancer vaccines"

Cancer vaccines are medicines designed to train the immune system to recognize and attack cancer cells, similar to giving the body a ‘wanted poster’ for tumor-specific traits. They can be preventative (stopping cancers caused by infections) or therapeutic (helping the body fight existing tumors). For investors, they matter because clinical trial results, regulatory approvals, and manufacturing success determine whether a promising therapy becomes a widely used, high-value product or fails in development.

AI-generated analysis. Not financial advice.

SAN JOSE, Calif., Dec. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Monday, December 15, 2025, at 1:00pm ET.

The Fireside Chat will be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and will cover several topics, including:

• The final data from Anixa's Phase 1 breast cancer vaccine trial—data which will have been presented on December 11, 2025, at the San Antonio Breast Cancer Symposium
• Implications for the application of the retired protein strategy for cancer vaccines
• Next steps for vaccine development

This event is open access for all investors to participate. Interested parties can register for the event through Water Tower Research at: Webinar Registration - Zoom

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-water-tower-research-fireside-chat-on-monday-december-15-2025-302637196.html

SOURCE Anixa Biosciences, Inc.

FAQ

When will Anixa (ANIX) present at the Water Tower Research Fireside Chat?

Anixa's CEO will present on December 15, 2025 at 1:00 PM ET.

Will Anixa (ANIX) discuss Phase 1 breast cancer vaccine results in the December 15, 2025 chat?

Yes; the chat will cover the final Phase 1 breast cancer vaccine data that were presented on December 11, 2025.

How can investors register for the Anixa (ANIX) Fireside Chat on December 15, 2025?

Investors can register via the Water Tower Research webinar registration link provided by the host.

What topics related to vaccines will Anixa (ANIX) address on December 15, 2025?

Topics include the retired protein strategy for cancer vaccines and planned next steps for vaccine development.

Who is representing Anixa (ANIX) at the Water Tower Research event?

Anixa will be represented by Chairman and CEO Dr. Amit Kumar.

Is the Water Tower Research Fireside Chat on December 15, 2025 open to all investors?

Yes; the event is described as open access for all investors to participate.